Susquehanna International Group, LLP Fate Therapeutics Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

22 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$3.26 - $7.08 $160,392 - $348,336	-49,200 Reduced 80.52%	11,900 $39,000
Q1 2024 May 07, 2024	BUY	$3.54 - $8.35 $216,294 - $510,185	61,100 New	61,100 $448,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $70,006 - $169,193	7,100 Added 33.97%	28,000 $282,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $130,448 - $223,572	6,200 Added 42.18%	20,900 $468,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $634,746 - $1.51 Million	-35,700 Reduced 70.83%	14,700 $364,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $629,004 - $1.28 Million	21,200 Added 72.6%	50,400 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $564,512 - $759,212	-11,800 Reduced 28.78%	29,200 $1.71 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $1.72 Million - $2.78 Million	-29,000 Reduced 41.43%	41,000 $2.43 Million
Q2 2021 Aug 11, 2021	SELL	$67.25 - $92.52 $2.85 Million - $3.92 Million	-42,400 Reduced 37.72%	70,000 $6.08 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $4.42 Million - $7.2 Million	61,300 Added 119.96%	112,400 $9.27 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $167,596 - $444,180	4,400 Added 9.42%	51,100 $4.65 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $790,660 - $1.05 Million	-26,000 Reduced 35.76%	46,700 $1.87 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $816,484 - $1.42 Million	-40,400 Reduced 35.72%	72,700 $2.49 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $825,984 - $1.52 Million	-47,800 Reduced 29.71%	113,100 $2.51 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $224,952 - $348,264	-16,800 Reduced 9.45%	160,900 $3.15 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $1.51 Million - $2.2 Million	-97,600 Reduced 35.45%	177,700 $2.76 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $1.19 Million - $1.56 Million	76,300 Added 38.34%	275,300 $5.59 Million
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $717,990 - $1.02 Million	54,600 Added 37.81%	199,000 $3.5 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $532,672 - $787,872	46,400 Added 47.35%	144,400 $1.85 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $539,000 - $1 Million	61,600 Added 169.23%	98,000 $1.6 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $90,684 - $133,452	-9,900 Reduced 21.38%	36,400 $413,000
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $291,690 - $637,551	46,300 New	46,300 $452,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$21.9 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$17.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$16.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$9.25 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$8.72 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account